Table 2.
Characteristics of vaccine breakthrough infections according to the severity of Covid-19.
| Total pts without previous infection | HOME-TREATED | HOSPITALIZED | p | |
|---|---|---|---|---|
| N = 231 | N = 205 | N = 26 | ||
| Male gender | 105/231 (45.5%) | 87/205 (42.4%) | 18/26 (69.2%) | 0.010 |
| Age at COVID diagnosis | 60.4 (49.8–73.2) | 57.4 (49.2–71.5) | 75.5 (67.3–84.3) | <0.001 |
| >70 | 71/231 (30.7%) | 55/205 (26.8%) | 16/26 (61.5%) | <0.001 |
| MPN diagnosis | ||||
| ET | 89/231 (38.5%) | 80/205 (39.0%) | 9/26 (34.6%) | 0.66 |
| PV | 75/231 (32.5%) | 68/205 (33.2%) | 7/26 (26.9%) | 0.52 |
| MF | 54/231 (23.4%) | 44/205 (21.5%) | 10/26 (38.5%) | 0.054 |
| Early/pre-PMF | 13/231 (5.6%) | 13/205 (6.3%) | 0/26 (0.0%) | 0.19 |
| Previous thrombosis | 36/231 (15.6%) | 30/205 (14.6%) | 6/26 (23.1%) | 0.26 |
| Mutational status | ||||
| JAK2 V617F | 166/227 (73.1%) | 147/203 (72.4%) | 19/24 (79.2%) | 0.48 |
| CALR | 34/136 (25.0%) | 32/126 (25.4%) | 2/10 (20.0%) | 0.70 |
| MPL | 7/131 (5.3%) | 6/123 (4.9%) | 1/8 (12.5%) | 0.36 |
| JAK2 EXON12 | 0/70 (0.0%) | 0/65 (0.0%) | 0/5 (0.0%) | |
| Spleen palpable | ||||
| No | 152/218 (69.7%) | 136/193 (70.5%) | 16/25 (64.0%) | |
| Yes | 64/218 (29.4%) | 55/193 (28.5%) | 9/25 (36.0%) | 0.60 |
| Previously splenectomized | 2/218 (0.9%) | 2/193 (1.0%) | 0/25 (0.0%) | |
| Size below costal margin (cm) | 5.0 (2.0–7.0) | 4.5 (2.0–7.0) | 6.0 (4.0–20.0) | 0.11 |
| MPN-treatment before COVID | ||||
| Phlebotomy | 38/230 (16.5%) | 36/204 (17.6%) | 2/26 (7.7%) | 0.20 |
| Cytoreduction pre-COVID | 167/230 (72.6%) | 144/204 (70.6%) | 23/26 (88.5%) | 0.054 |
| Type: | ||||
| HU | 93/231 (40.3%) | 83/205 (40.5%) | 10/26 (38.5%) | 0.84 |
| Anagrelide | 19/231 (8.2%) | 19/205 (9.3%) | 0/26 (0.0%) | 0.11 |
| Interferon | 5/231 (2.2%) | 5/205 (2.4%) | 0/26 (0.0%) | 0.42 |
| Ruxolitinib | 40/231 (17.3%) | 29/205 (14.1%) | 11/26 (42.3%) | <0.001 |
| Other | 11/231 (4.8%) | 9/205 (4.4%) | 2/26 (7.7%) | 0.36 |
| Characteristics of Covid-19 | ||||
| Wave | ||||
| 2 (Alpha, Beta, Gamma) | 14/231 (6.1%) | 11/205 (5.4%) | 3/26 (11.5%) | 0.20 |
| 3 (Delta) | 94/231 (40.7%) | 79/205 (38.5%) | 15/26 (57.7%) | 0.061 |
| 4 (Omicron) | 123/231 (53.2%) | 115/205 (56.1%) | 8/26 (30.8%) | 0.015 |
| COVID-19 severitya | ||||
| Asymptomatic infection | 11/220 (5.0%) | 11/197 (5.6%) | 0/23 (0.0%) | 0.61 |
| Mild Illness | 190/220 (86.4%) | 180/197 (91.4%) | 10/23 (43.5%) | <0.001 |
| Moderate Illness | 6/220 (2.7%) | 4/197 (2.0%) | 2/23 (8.7%) | 0.12 |
| Severe/critical Illness | 13/220 (5.9%) | 2/197 (1.0%) | 11/23 (47.8%) | <0.001 |
| Respiratory support | 19/231 (8.2%) | 3/205 (1.5%) | 16/26 (61.5%) | <0.001 |
| ICU | 5/230 (2.2%) | 1/204 (0.5%) | 4/26 (15.4%) | <0.001 |
| Saturation | 98.0 (96.0–99.0) | 98.0 (97.0–99.0) | 92.0 (88.0–94.0) | <0.001 |
| Lab values at COVID diagnosis | ||||
| Hb | 12.9 (11.3–14.0) | 13.0 (11.5–14.1) | 11.5 (9.0–13.1) | 0.002 |
| HCT | 40.0 (36.0–44.0) | 40.5 (36.7–44.5) | 37.5 (27.3–40.1) | 0.004 |
| RDW | 16.5 (14.3–18.7) | 16.0 (13.9–18.1) | 18.3 (15.4–18.9) | 0.093 |
| WBC | 7.5 (5.5–10.5) | 7.5 (5.7–10.2) | 8.1 (4.8–11.5) | 0.93 |
| Neutrophils | 68.9 (56.9–76.0) | 67.1 (56.3–75.0) | 75.3 (63.0–82.8) | 0.028 |
| Lymphocytes | 18.2 (10.9–26.8) | 19.8 (12.0–28.2) | 13.1 (7.4–18.5) | 0.005 |
| Neutrophils/lymphocytes ratio | 3.6 (2.1–6.0) | 3.3 (2.0–5.3) | 5.9 (3.6–10.2) | <0.001 |
| PLT | 401.0 (226.0–608.5) | 430.0 (274.0–622.0) | 199.0 (119.0–294.0) | <0.001 |
| LDH | 243.0 (200.0–470.0) | 236.5 (191.0–447.0) | 415.0 (269.0–573.0) | 0.022 |
| CRP | 8.9 (1.4–32.9) | 2.0 (0.9–16.0) | 33.1 (17.0–123.0) | <0.001 |
| Fibrin | 402.0 (339.0–579.0) | 339.0 (309.0–480.0) | 432.0 (360.0–726.0) | 0.12 |
| D-dimer | 510.0 (270.0–759.0) | 331.5 (185.0–568.5) | 650.0 (440.0–910.0) | 0.015 |
| Vaccine information | ||||
| Months from last vaccine dose to infection | 4.0 (1.4–6.6) | 4.0 (1.5–6.7) | 2.6 (1.2–6.0) | 0.37 |
| N° administered doses | ||||
| Only 1 dose | 22/231 (9.5%) | 19/205 (9.3%) | 3/26 (11.5%) | 0.90 |
| 2 doses | 115/231 (49.8%) | 103/205 (50.2%) | 12/26 (46.2%) | |
| 3–4 doses | 94/231 (40.7%) | 83/205 (40.5%) | 11/26 (42.3%) | |
| Vaccine type | ||||
| Pfizer/BioNTech | 179/231 (77.5%) | 164/205 (80.0%) | 15/26 (57.7%) | 0.010 |
| Moderna | 28/231 (12.1%) | 22/205 (10.7%) | 6/26 (23.1%) | 0.069 |
| AstraZeneca | 18/231 (7.8%) | 14/205 (6.8%) | 4/26 (15.4%) | 0.13 |
| Johnson&Johnson | 5/231 (2.2%) | 4/205 (2.0%) | 1/26 (3.8%) | 0.45 |
| UNK | 1/231 (0.4%) | 1/205 (0.5%) | 0/26 (0.0%) | – |
| Outcome | ||||
| Death | 5/231 (2.2%) | 2/205 (1.0%) | 3/26 (11.5%) | 0.011 |
aAccording to the NIH COVID-19 Treatment Guidelines.